<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="67160">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01939639</url>
  </required_header>
  <id_info>
    <org_study_id>OXT_PS_2013</org_study_id>
    <secondary_id>PS_2013</secondary_id>
    <nct_id>NCT01939639</nct_id>
  </id_info>
  <brief_title>The Influence of Oxytocin on the Processing of Social Contact</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Bonn</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital, Bonn</source>
  <oversight_info>
    <authority>Germany: Ethics Commission</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Social touch can convey the most potent and salient of socio-emotional signals. While the
      hypothalamic peptide oxytocin (OXT) has been identified as a key neurochemical mediator of
      grooming in some other social species, its modulatory influence on human interpersonal touch
      is unknown. The investigators expect that OXT augments the hedonic value of touch and that
      this behavioral effect is paralleled at the neural level by an increased response in brain
      areas mediating rewarding aspects of social touch.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>March 2013</start_date>
  <completion_date type="Actual">August 2013</completion_date>
  <primary_completion_date type="Actual">June 2013</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science</study_design>
  <primary_outcome>
    <measure>Pleasantness ratings of social touch</measure>
    <time_frame>30 minutes after the nasal spray administration</time_frame>
    <safety_issue>No</safety_issue>
    <description>After each trial, subjects are asked to use a visual analog scale to rate the pleasantness of the administered touch.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Blood-oxygen-level dependent signal in response to social touch</measure>
    <time_frame>30 minutes after the nasal spray administration</time_frame>
    <safety_issue>No</safety_issue>
    <description>By using functional magnetic resonance imaging we want to examine oxytocin's effects on the neural correlates (BOLD signal) of social touch.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Questionnaire measurement of mood (PANAS) and anxiety (STAI).</measure>
    <time_frame>15 minutes before the nasal spray administration and (on average) 10 minutes after the fMRI experiment</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <other_outcome>
    <measure>Saliva oxytocin concentrations</measure>
    <time_frame>15 minutes before the nasal spray administration and (on average) 10 minutes after the fMRI experiment</time_frame>
    <safety_issue>No</safety_issue>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">40</enrollment>
  <condition>Healthy Male Volunteers</condition>
  <arm_group>
    <arm_group_label>Oxytocin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>24 IU Oxytocin, intranasal application 30 min prior to the experiment</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>intranasal application, sodium chloride solution, 3 puffs per nostril</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>intranasal application, sodium chloride solution, 3 puffs per nostril</description>
    <arm_group_label>Placebo</arm_group_label>
    <other_name>Placebo</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Oxytocin</intervention_name>
    <description>24 IU Oxytocin, intranasal application 45 min prior to the experiment</description>
    <arm_group_label>Oxytocin</arm_group_label>
    <other_name>Syntocinon</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Healthy male volunteers

        Exclusion Criteria:

        Current or past psychiatric disease Current or past physical illness Psychoactive
        medication Tobacco smokers
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Department of Psychiatry, University of Bonn</name>
      <address>
        <city>Bonn</city>
        <state>North Rhine-Westphalia</state>
        <zip>53105</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <link>
    <url>http://renehurlemann.squarespace.com/welcome/</url>
  </link>
  <verification_date>September 2013</verification_date>
  <lastchanged_date>September 5, 2013</lastchanged_date>
  <firstreceived_date>August 27, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University Hospital, Bonn</investigator_affiliation>
    <investigator_full_name>Rene Hurlemann</investigator_full_name>
    <investigator_title>MD PhD M.Sc.</investigator_title>
  </responsible_party>
  <keyword>Oxytocin</keyword>
  <keyword>fMRI</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Oxytocin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
